100 results about "Treatment refractory" patented technology

Methods of treating a refractory or drug resistant cancer, cell proliferative disorder and tumor cells are provided. Also provided are antibody drug conjugate metabolites.

The present invention is directed to methods for the treatment of treatment-refractory depression or treatment-resistant depression comprising administering to a patient in need thereof, a therapeutically effective amount of esketamine as mono-therapy or as combination therapy with at least on antidepressant.

The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and / or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and their use alone or in combination with additional psychotherapeutic compositions in the treatment of conditions affected by monoamine neurotransmitters, including treatment of refractory individuals.

Methods of treating a refractory or drug resistant cancer, cell proliferative disorder and tumor cells are provided.

Disclosed are methods and materials for inhibiting (e.g., treating or preventing) uveitis in a subject, including treatment refractory uveitis, using anti-IL-1β binding molecules (e.g., IL-1β binding antibodies or binding fragment thereof).

The present invention is directed to methods for the treatment of treatment-refractory depression or treatment-resistant depression comprising administering to a patient in need thereof, a therapeutically effective amount of esketamine as mono-therapy or as combination therapy with at least on antidepressant.

The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to treat refractory cancers using Na+ / K+-ATPase inhibitors, such as cardiac glycosides, including bufadienolides or their corresponding aglycones (e.g., proscillaridin, scillaren, and scillarenin, etc.), especially in oral formulations and / or solid dosage forms containing more than 1 mg of active ingredients.

The present invention relates to amino-salicylic-aminophenyl compounds for use in the treatment of the inflammatory component of celiac disease. These compounds act by blocking the cytokines released in celiac disease and are specifically useful in the treatment of refractory cases.

Intractable neuronal diseases are treated by inducing differentiation of neural stem cells into neurons without accompanying a risk such as cytotoxicity and infection. Intractable neuronal diseases, such as Parkinson's disease, cerebral infarction, Alzheimer's disease, spinal cord injury, brain contusion, amyotropic lateral sclerosis, Huntington's disease, malignant tumor, and the like, are treated by regeneration therapy by transferring VHL peptides which can induce differentiation of neural stem cell into neurons into neural stem cells to induce differentiation of neural stem cells into neurons or by administering VHL peptides directly into a human body to induce differentiation of endogeneous stem cells into neurons.

The present invention relates to a neuronal differentiation method of adult stem cells using small molecules, more particularly to a method for inducing differentiation of adult stem cells into nerve cells using small molecules, which enables effective differentiation into nerve cells and, thus, is useful in treating intractable CNS disorders such as Parkinson's disease, dementia, Alzheimer's disease and spinal cord injury.

The present invention relates to an agent for reducing scar formation, which inhibits the scar formation by injecting sodium bicarbonate to the dermis tissue of the wound with a syringe to directly control pH of the wound site, namely, by alkalinizing the wound to inactivate TGF-beta. According to the present invention, the agent for reducing scar formation by controlling the wound healing process can be clinically and immediately applied to the treatment of tylosis scar and keloid, etc., and is effective to the treatment of intractable fibrosis diseases. Also, the invention can be widely applied in many ways as an easy tool which can control the action of TGF-beta in a living organism.

An object of the present invention is to provide methods for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease. The object can be achieved by a method for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease in a patient in need of the prevention or treatment of the inflammatory bowel disease, comprises administering an effective amount of adrenomedullin, a modified product thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, or a salt thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, to the patient.

The invention provides a pharmaceutical composition containing sodium hyaluronate with the relatively medium molecular weight and chondroitin sulfate with the relatively low molecular weight. The molecular weight of sodium hyaluronate is 200 kD-1,000 kD, the concentration of sodium hyaluronate is 1%-2%, the molecular weight of chondroitin sulfate is 5 kD-10 kD, and the concentration of chondroitin sulfate is 1.5%-3%. The pharmaceutical composition contains chondroitin sulfate with the relatively low molecular weight, has the better treatment effect than single sodium hyaluronate and can be used for treating refractory nonbacterial cystitis, Chronic recurrent bacterial cystitis, radiation-induced cystitis, interstitial cystitis (the chronic bladder pain syndrome) and neurogenic bladder urinary system infection.

Provided herein are methods for treating neuropsychiatric disorders by delivering radiation to an area in the subgenual anterior cingulate cortex, particularly to the cingulate area 25. Those methods are also beneficial to treat refractory neuropsychiatric disorders.

The present invention relates to multipotent adult stem cells expressing Oct4, derived from umbilical cord blood (UCB) and also these cell are expressing CD29, CD31, CD44, simultaneously, a method for preparing the same, and more specifically to multipotent adult stem cells which are obtained by culturing umbilical cord blood-derived monocytes in a medium containing bFGF (basic fibroblast growth factor) and human serum or plasma. In addition, multipotent adult stem cells expressing Oct-4 from UCB are morphologically spindle or round shaped cells Although the stem cells according to the present invention are adult stem cells, they are multipotent and capable of differentiating into ectodermal-, messodermal-, endodermal-originated tissue or cells including osteogenic cells or nerve cells etc, thus they can be effectively used in the treatment of intractable diseases and incurable diseases.

The invention relate to a ketogenesis mixture preparation applicable for treating refractory epilepsy, which is characterized in that: (1) fat, protein and carbohydrate form the basic prescription, a small amount of essential vitamins, minerals and aminophenol promoting the growth and the development of the human body and brain and promoting the metabolism are added in the basic prescription; (2) in the basic preparation, the weight percentages of the components are respectively that: fat 70-80 percent, protein 15-20 percent, carbohydrate 5-10 percent; (3) the physical states of all the components in the basic preparation are powder, ointment, aqua, or solid state agent. The physical states of the ketogenesis mixture preparation are powder granule, electuary, liquid agent, tablet, capsule or other solid state agent. The ketogenesis mixture preparation aims at the special nutrition requirement of Chinese, nutritional ingredient promoting the development of the brain and the metabolism is added in, the curative efficiency on refractory epilepsy reaches 80 percent, which reaches or exceeds the curative effect of the equivalent product abroad.

This invention is directed to potent inhibitors of protein tyrosine kinase alone or in synergistic combination with antiangiogenic or chemotherapeutic agents for the abrogation of mature vasculature within chemotherapeutic refractory tumors, pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders / conditions involving cell proliferation, and particularly treatment of brain cancer, ovarian cancer, pancreatic cancer prostate cancer, and human leukemias, such as CML, AML or ALL.

The invention discloses a primer group, a kit and a detection method for detecting genes related to individualized medication for depression. The primer group is selected from nucleotide sequences inSEQ ID NO.1-SEQ ID NO.154. The detection kit covers eight major categories of clinical first-line and second-line antidepressant efficacy-related genes, and relates to drug metabolism, target spots and transporter gene loci, and detection is conducted comprehensively and accurately. Accordingly, aiming at part of patients suffering from treatment-refractory depression, gene detection related to the therapeutic effect of antidepressant synergistic drugs is added, and powerful support is provided for selection of therapeutic schedules of the treatment-refractory depression.

The present invention relates to a method for treating a refractory or relapsed lung cancer. Particularly, the invention provides a method and a formulation of using an immunomodulatory protein derived from Ganoderma microsporum in the treatment of a refractory or relapsed lung cancer.

The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and / or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and their use alone or in combination with additional psychotherapeutic compositions in the treatment of conditions affected by monoamine neurotransmitters, including treatment of refractory individuals.

The invention discloses a compound medicine preparation for treating refractory hypertension, which is mainly prepared from the following components in parts by weight: 50 to 500 parts of ganoderan, 5 to 10 parts of nifedipine, 12.5 to 50 parts of captopril, 10 to 50 parts of hydrochlorothiazide and 12.5 to 100 parts of atenolol. According to the compound medicine preparation provided by the invention, the ganoderan is compounded with multiple antihypertensive drugs of conventional multiple-treatment to prepare a convenient-to-take compound preparation; the beneficial effects of synergetic antihypertensive effect and mutual side effect relieving / offsetting effect of the ganoderan and the four medicines are realized, the compliance of standardized medicine-taking of refractory hypertension patients is obviously improved, the therapeutic effect of obviously reducing the blood pressure level of the refractory hypertension or even realizing up-to-standard blood pressure control on part of the patients are achieved, and a novel convenient-to-take compound antihypertensive drug is provided for simplifying the drug use of the refractory hypertension patients and effectively reducing the blood pressure level.

Provided are a deuterium-substituted dehydrophenylahistin-like compound, preparation method thereof and use in a preparation of antitumor drugs. The deuterium-substituted dehydrophenylahistin-like compound has a structure of general formula (I), and a synthesis method thereof comprises: firstly conducting a condensation reaction of diacetyldiketopiperazine and an aldehyde intermediate a or a deuterated aldehyde compound b to form a heterocyclic compound c or a deuterium-containing heterocyclic compound d, which is then subjected to a condensation reaction with benzaldehyde and a deuterium-substituted benzaldehyde-like compound to form the deuterium-substituted dehydrophenylahistin-like compound. Also provided are a highly effective deuterated aldehyde intermediate with a high deuterium substitution rate and a deuterium-containing heterocycle intermediate, and a synthesis method thereof. An experiment shows that the deuterium-substituted dehyd-rophenylahistin-like compound provided by the present invention has an effect on tubulin depolymerization and can treat a refractory solid tumor or lymphoma. The present invention provides a method for researching and developing antitumor drugs of the related compound.

The invention relates to biological gel for treating refractory skin damage and application of the biological gel. The biological gel is prepared from umbilical cord mesenchymal stem cells coated by biocompatible degradable gel with special stem cell culture additives, wherein the stem cell culture additives comprise umbilical cord mesenchymal stem cells, traditional Chinese medicine extracts and serum. The biological gel provided by the invention is capable of promoting normal body cell proliferation, reducing influence of common negative irritation such as anoxia and chemotherapy to normal body cells, prolonging cell growth time, promoting cell factor secretion and effectively treating refractory skin damage such as burning and scalding, and is safe and efficient, small in side effect, simple to product and low in cost.

The invention relates to application of SB202190 in preparation of medicines for treating intractable epilepsy. By utilizing an intractable epilepsy animal model, due to a series of researches, the SB202190 can reduce the expression of multidrug transporter-P glycoprotein (PGP) related to drug tolerance in the brain of an intractable epilepsy rat, the drug concentration of antiepileptic drugs (AEDs) in hippocampus cell extracellular fluid of the intractable epilepsy rat is improved, the AEDs is assisted to improve the electrophysiological activity of the rat, and the ignition post-attack classification is reduced, namely the drug tolerance of the intractable epilepsy can be improved by the SB202190. The application of the SB202190 is widened, and an effective way is provided for treatment of the intractable epilepsy.

Provided are a deuterium-substituted dehydrophenylahistin-like compound, preparation method thereof and use in a preparation of antitumor drugs. The deuterium-substituted dehydrophenylahistin-like compound has a structure of general formula (I), and a synthesis method thereof comprises: firstly conducting a condensation reaction of diacetyldiketopiperazine and an aldehyde intermediate a or a deuterated aldehyde compound b to form a heterocyclic compound c or a deuterium-containing heterocyclic compound d, which is then subjected to a condensation reaction with benzaldehyde and a deuterium-substituted benzaldehyde-like compound to form the deuterium-substituted dehydrophenylahistin-like compound. Also provided are a highly effective deuterated aldehyde intermediate with a high deuterium substitution rate and a deuterium-containing heterocycle intermediate, and a synthesis method thereof. An experiment shows that the deuterium-substituted dehydrophenylahistin-like compound provided by the present invention has an effect on tubulin depolymerization and can treat a refractory solid tumor or lymphoma. The present invention provides a method for researching and developing antitumor drugs of the related compound.

The invention relates to a traditional Chinese medicine composition for treating the refractory gastroesophageal reflux disease. The composition is produced through medicinal materials of inula stems, mangnolia officinalis, coptis, fructus evodiae, ginger, calcined flute, Chinese thorowax roots, corydalis tuber, rhizoma cyperi, stir-baked fructus gardenia, bitter orange, sealwort, radix paeoniae alba and liquorice. The invention further provides an application of the traditional Chinese medicine composition. The traditional Chinese medicine composition and the application have the advantages that the composition is used for treating the refractory gastroesophageal reflux disease, symptoms of substernal pains and discomfort, throat discomfort, heartburn, sour regurgitation, belching and the like are improved apparently, and the clinical efficacy rate is high.

Application of a quinonemethide triterpenoid or a pharmaceutically tolerable salt, solvate or anhydrate thereof in preparing medicine for the treatment of refractory rheumatoid arthritis, and application in medicine for inducing autophagy in a synovial fibroblast. Further a pharmaceutical composition includes an effective dose of a quinonemethide triterpenoid and an anti-arthritis compound. The quinonemethide triterpenoid is suitable to treat refractory rheumatoid arthritis (RA), in particular ABC-protein-dependent RA and apoptosis-deficient RA. The quinonemethide triterpenoid also possesses significant inhibitory effects on the growth of synovial fibroblasts, in particular modulating the calcium homeostasis in multidrug-resistant rheumatoid arthritis synovial fibroblasts.

Disclosed are methods for treating one or more mammalian cancers, and in particular, methods for treating human breast cancer employing one or more iNOS pathway-inhibitory compounds, either alone, or in combination with one or more selected antihypertensive agents, including calcium channel antagonists, either alone, and further in combination with one or more conventional chemotherapeutic or anti-cancer regimens. Also disclosed are particular therapeutic formulations including these compositions, and methods for their use in treating refractory, metastatic, and relapsed cancers, and for managing or reversing treatment resistance in human triple-negative breast cancers in particular.

The present invention relates to the treatment of multiple myeloma, especially for the treatment of those patients with refractory or first relapsed multiple myeloma, and in particular patients with t(4;14) multiple myeloma, comprising administration of a tyrosine kinase inhibitor or a mast cell inhibitor, especially masitinib or a pharmaceutically acceptable salt thereof, administered in association with an additional care in multiple myeloma; for example, autologous stem-cell transplantation, targeted therapies, anti-myeloma agents such as alkylating agents, corticosteroids, or immunomodulatory agents, including bortezomib, lenalidomide, and dexamethasone.